Healthy Extracts (HYEX) Net Income towards Common Stockholders (2015 - 2026)
Healthy Extracts (HYEX) posted quarterly Net Income towards Common Stockholders of -$515995.0 for Q4 2025, down 165.83% year-over-year from $783876.3 in Q4 2024, and up 22.26% quarter-over-quarter from -$663710.0 in Q3 2025.
Healthy Extracts (HYEX) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
Healthy Extracts' Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$515995.0 for Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders fell 165.83% year-over-year to -$515995.0; the TTM figure through Dec 2025 stood at -$1.6 million (down 115.31% YoY), while the FY2025 annual figure was -$1.2 million, down 308.13% from the prior year.
- Net Income towards Common Stockholders for Q4 2025 stood at -$515995.0, up from -$663710.0 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$23169.0 in Q3 2024, with the low at -$1.8 million in Q2 2023.
- The 5-year median for Net Income towards Common Stockholders is -$328946.0 (2023), against an average of -$445314.2.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders soared 97.18% in 2024, then plunged 2764.65% in 2025.
- Healthy Extracts' Net Income towards Common Stockholders stood at -$662057.0 in 2021, then surged by 70.2% to -$197326.0 in 2022, then slumped by 79.74% to -$354667.0 in 2023, then surged by 45.27% to -$194110.0 in 2024, then slumped by 165.83% to -$515995.0 in 2025.
- Business Quant data shows HYEX's Net Income towards Common Stockholders at -$515995.0 in Q4 2025, -$663710.0 in Q3 2025, and -$197917.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Healthy Extracts | 19.90 Mn | 19.71 Mn | 1.45 Mn | -48,762.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -141,018.00 |
| Dec 31, 2025 | -515,995.00 |
| Sep 30, 2025 | -663,710.00 |
| Jun 30, 2025 | -197,917.00 |
| Mar 31, 2025 | -220,529.00 |
| Dec 31, 2024 | -194,110.00 |
| Sep 30, 2024 | -23,169.00 |
| Jun 30, 2024 | -221,741.00 |
| Mar 31, 2024 | -303,225.00 |
| Dec 31, 2023 | -354,667.00 |
| Sep 30, 2023 | -822,950.00 |
| Jun 30, 2023 | -1.76 Mn |
| Mar 31, 2023 | -411,114.00 |
| Dec 31, 2022 | -197,326.00 |
| Sep 30, 2022 | -286,276.00 |
| Jun 30, 2022 | -793,972.00 |
| Mar 31, 2022 | -45,652.00 |
| Dec 31, 2021 | -662,057.00 |
| Sep 30, 2021 | -385,315.00 |
| Jun 30, 2021 | -254,709.00 |